Fig. 3
From: Factors affecting long-term efficacy of T regulatory cell-based therapy in type 1 diabetes
The levels of different phenotypes of Tregs and their correlation. a The percentage of Tregs measured as CD3+ CD4+ FoxP3+ cells during the follow-up. The p values show the significance in Kruskal–Wallis ANOVA comparisons between three groups at day 0 (*), 4th (&) and 12 month (#). b The percentage of FoxP3+ cells measured in the CD3+ CD4+ CD25highCD127− gate. The p values and the lines represent the significance of Wilcoxon test comparisons: day 0 vs. 24th month in particular groups and **p represents the significance of Kruskal–Wallis ANOVA comparison between three groups at the 24th month. The values for untreated controls (NO Tregs), patients treated with a single infusion (single dose), and patients treated with two infusions (two doses) of Tregs are presented as medians (min.–max.); the open circles represent values from particular patients. c Spearman’s rank correlation between CD3+ CD4+ FoxP3+ and CD3+ CD4+ CD25highCD127-phenotypes used to assess the percentage of Tregs in the follow-up (R and p are given for particular groups)